The present invention is directed to particular monoclonal antibodies and fragments thereof that find use in the detection and isolation of in vitro differentiated cardiomyocytes. In particular, the present invention relates to LSMEM2 biomarkers, including monoclonal antibodies having specificity for cell surface protein LSMEM2 and to methods of using such biomarkers for diagnosis of cardiovascular injury.